GV co-leads $27.1M Series A in Oxford Uni life sciences spinout Vaccitech

 Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine. Read More

Responses are currently closed, but you can trackback from your own site.

Comments are closed.